Publication:
Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer

Placeholder

Organizational Units

Authors

Bayrak, Mehmet
Ölmez, Ömer Fatih
Kurt, Ender
Çubukçu, Erdem
Evrensel, Türkkan
Kanat, Özkan
Manavoǧlu, Osman

Authors

Advisor

Language

Publisher:

Springer

Journal Title

Journal ISSN

Volume Title

Abstract

Overexpression of the gene c-erbB2, which encodes a receptor tyrosine kinase, has been associated with prognosis and response to therapy in several solid tumors. This study was designed to test whether c-erb-B2 overexpression can be related to prognosis of patients with metastatic gastric cancer. Between 2005 and 2010, 46 cases of metastatic gastric cancer were evaluated immunohistochemically for c-erb-B2 overexpression. Overall survival (OS) and time-to-progression (TTP) served as the main outcome measures. c-erbB2 was overexpressed in 19 (41.3 %) cases and 8 patients (17.4 %) had a c-erbB2 score of 3+ (a strong complete membrane staining observed in > 10 % of the tumor cells). c-erbB2 expression was not associated with the clinicohistological characteristics of the study participants. The mean OS was 11.48 +/- A 1.03 months, whereas the mean TTP was 8.28 +/- A 0.8 months. Compared with patients with a score of 2+ or less (n = 38), those with a c-erbB2 score of 3+ (n = 8) had both a significantly lower OS (15.55 +/- A 1.63 vs. 8.22 +/- A 0.88 months, respectively, p < 0.05) and TTP (10.72 +/- A 1.81 vs. 6.11 +/- A 0.61 months, respectively, p < 0.05). After allowance for potential confounders, Cox regression analysis identified a c-erbB2 score of 3+ as an independent predictor of both OS (hazard ratio = 1.9; 95 % confidence interval = 1.1-3.7, p < 0.05) and TTP (hazard ratio = 1.8; 95 % confidence interval = 1.1-4.1, p < 0.05). Our results suggest that c-erbB-2 overexpression may have a prognostic significance in patients with metastatic gastric cancer.

Description

Source:

Keywords:

Keywords

Oncology, C-erbB2, Gastric cancer, Metastasis, Immunohistochemistry, Prognosis, Expression, Trastuzumab, Breast, Her2

Citation

Bayrak, M. vd. (2013). "Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer". Clinical and Translational Oncology, 15(4), 307-312.

Endorsement

Review

Supplemented By

Referenced By

8

Views

0

Downloads